American Society of Hypertension annual meeting, New York, NY (PRWEB) May 3, 2010
InterCure, Inc., a wholly owned subsidiary of InterCure Ltd. (Tel Aviv Stock Exchange: INCR), and Omron Healthcare Inc., a wholly owned subsidiary of Omron Healthcare Group and Omron Corporation , announced a joint marketing agreement to strengthen the link between hypertension diagnostics and therapies in the consumer, professional and pharmacy markets. The wide-reaching agreement leverages the companies’ complementary strengths and aims to build programs to assist the 75 million Americans with hypertension and their healthcare providers. Omron is a leading manufacturer of blood pressure monitors and InterCure manufactures RESPeRATE®, the world’s only medical device clinically proven to lower blood pressure through respiratory modulation therapy.
As part of the collaboration, InterCure and Omron have begun promoting a new online destination, the LowerPressure website (http://www.lowerpressure.com) to provide a support community to millions of hypertensive patients.
At the American Society of Hypertension annual meeting, the two companies will have adjacent exhibit booths (#1010, #1012).
About InterCure Ltd. and RESPeRATE
InterCure Ltd. (Tel-Aviv Stock Exchange: INCR) is disrupting the $42 billion hypertension industry with the world's first FDA-cleared, OTC blood pressure treatment device, RESPeRATE® (http://www.resperate.com). In a market where seven out of 10 hypertensives are NOT controlled despite the availability of more than 100 blood pressure medications, RESPeRATE provides an effective adjunctive non-drug therapy with no side effects.
RESPeRATE has gained widespread support of hypertension specialists and has secured regulatory clearance in most key international markets. Ten separate clinical studies have proven the device's efficacy and safety, and RESPeRATE is now featured in more than 20 popular and professional text books.
With more than 100,000 units sold, thousands of supportive clinicians worldwide and one of the world's most popular hypertension websites, InterCure is now introducing RESPeRATE into retail pharmacies to increase access to hypertension sufferers.
InterCure has an exciting product pipeline based on its broadly-patented "Device-Guided Breathing" technology platform. This technology enables a systematic reduction in sympathetic outflow of the autonomic nervous system, one of the key underlying causes of cardiovascular disease, insomnia and several other medical conditions.
About Omron Healthcare, Inc.
Omron Healthcare, Inc., located in Bannockburn, IL, is the North and South American sales and marketing office of Omron Healthcare Group, a leading manufacturer and distributor of blood pressure monitors for home use. With 100 million monitors sold worldwide to date, Omron Healthcare Group was the first to introduce manual and digital blood pressure monitors into the home healthcare market. Omron Healthcare offers innovative products and medical devices for use in sites ranging from hospitals to the home in the blood pressure monitoring, fitness diagnostics, thermometry, and respiratory categories. Omron Healthcare markets clinically proven products that provide accurate health information to consumers and physicians and support positive lifestyle changes and health improvement. For more information, visit http://www.omronhealthcare.com.
This news release may contain forward-looking statements that are based on the Company’s current beliefs and assumptions and on information currently available to its management. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. As a result of these risks, uncertainties and other factors, readers are cautioned not to place undue reliance on any forward-looking statements included in this press release. These forward-looking statements represent beliefs and assumptions only as of the date of this news release, and the Company assumes no obligation to update these forward-looking statements publicly, even if new information becomes available in the future.